沙利度胺对晚期肺腺癌并恶液质综合征的疗效研究  

The study of thalidomide in the treatment of advanced lung adenocarcinoma with CACS

作　　者：王希方 秦思达[2] 任宏[2] 白俊[1] 何莉[1] 王海鹏[1] 刘屹[1] 王维佳 陆王锋 Wang Xifang;Qin Sida;Ren Hong;Bai Jun;He Li;Wang Haipeng;Liu Yi;Wang Weijia;Lu Wangfeng(Department of Medical Oncology,Shaanxi Provincial People's Hospital,Shaanxi Xi'an 710068,China;Department of Thoracic Surgery,the First Affiliated Hospital,Xi'an Jiaotong University,Shaanxi Xi'an 710061,China;Department of Gastrointestinal Surgery,Shangluo Central Hospital,Shaanxi Shangluo 726000,China)

机构地区：[1]陕西省人民医院肿瘤内科,陕西西安710068 [2]西安交通大学第一附属医院胸外科,陕西西安710061 [3]商洛市中心医院胃肠外科,陕西商洛726000

出　　处：《现代肿瘤医学》2019年第24期4359-4362,共4页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:81402506)

摘　　要：目的:评价沙利度胺对晚期肺腺癌并CACS治疗的有效性和安全性。方法:选取210例体重减轻10%以上的,确诊晚期肺腺癌并发恶液质的患者,随机分为实验组和对照组。治疗组每晚服用沙利度胺100 mg,维持治疗8周,同时两组均给予营养支持,主要评价标准是体重和营养状况的变化。结果:用药8周后,204例(对照组104例,实验组100例)用于评估,治疗组在治疗前后平均体重、食欲、ECOGPS评分、乏力的改善均具有统计学意义。便秘、过度镇静在两组间有统计学差异(P=0.002和P=0.004),其他症状均无统计学差异。结论:沙利度胺对缓解晚期肺腺癌并发恶液质患者治疗有效,且耐受良好。Objective:To evaluate the efficacy and safety of thalidomide in treatment of CACS of advanced lung adenocarcinoma.Methods:210 patients whose weight loss over 10%,with advanced lung adenocarcinoma and CACS,were randomly divided into trail group and control group.The trail group was given a daily dose of thalidomide 100 mg for 8 weeks,while patients of two groups were given nutritional support.The main criteria were changes in weight and nutritional status.Results:204 cases(control group 104 cases,the trail group 100 cases)used to evaluate after 8 weeks.The average body weight,appetite,ECOGPS score and the improvement of fatigue had statistical significance in the trail group after treatment.Constipation and somnolence had difference statistically between the two groups(P=0.002 and P=0.004 respectively),and other symptoms had no statistical difference.Conclusion:Thalidomide is effective and well tolerated in the treatment of patients with advanced lung adenocarcinoma complicated with CACS.

关 键 词：晚期肺腺癌 恶液质 沙利度胺 安全性 疗效 

分 类 号：R734.2[医药卫生—肿瘤]